Ironwood Pharmaceuticals
IRWD
About: Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Employees: 253
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
18% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 51
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
6.71% less ownership
Funds ownership: 97.22% [Q1] → 90.51% (-6.71%) [Q2]
23% less funds holding
Funds holding: 201 [Q1] → 155 (-46) [Q2]
54% less capital invested
Capital invested by funds: $229M [Q1] → $105M (-$124M) [Q2]
70% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 64
Financial journalist opinion
